Oncology Scientific Papers
Achieving virological control in pan-resistant HIV-1 infection: A case series
2022
Diana Canetti, Camilla Muccini, Vincenzo Spagnuolo, Laura Galli, Andrea Poli, Nicola Gianotti, Marcello Feasi, and Antonella Castagna,
The Lancet Vol 77 Month March, 2022 11
TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer
2021
Author Demeule M, Charfi C, Currie JC, Laroque A, Zgheib A, Kozelko S, Béliveau R, Marsolais C, Annabi B
Demeule M, Charfi C, Currie J-C, et al. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. Cancer Sci. 2021;00:1–18.
TH1901, a novel curcumin-peptide conjugate for the treatment of Sortilin-positive (SORT1+) cancer [abstract].
2020
Cancer Res.
Annabi B, Demeule M, Currie J-C, et al.
80(16 suppl):6362. Proceedings of the Annual Meeting of the American Association for Cancer Research 2020.
TH1901, a novel curcumin-peptide conjugate for the treatment of Sortilin-positive (SORT1+) cancer.
2020
Annabi B, Demeule M, Currie J-C, et al.
Poster #4386 presented at: Annual Meeting of the American Association for Cancer Research; June 22-24, 2020; virtual.
Increasing potency of anticancer drugs through Sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer [abstract].
2020
Cancer Res.
Marsolais C, Demeule M, Currie J-C, et al.
80(16 suppl):1061. Proceedings of the Annual Meeting of the American Association for Cancer Research 2020.